financetom
Business
financetom
/
Business
/
Blackbaud Q3 revenue beats estimates, EPS exceeds expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blackbaud Q3 revenue beats estimates, EPS exceeds expectations
Oct 29, 2025 4:44 AM

Overview

* Blackbaud ( BLKB ) Q3 revenue of $281.1 mln beats analyst expectations

* Adjusted EPS of $1.10 for Q3 beats consensus

* GAAP revenue down 1.9% due to EVERFI divestiture, non-GAAP organic revenue up 5.2%

Outlook

* Blackbaud ( BLKB ) reiterates 2025 revenue guidance of $1.120 bln to $1.130 bln

* Company raises 2025 adjusted free cash flow guidance to $195 mln-$205 mln

* Blackbaud ( BLKB ) expects 2025 non-GAAP EPS of $4.30 to $4.50

Result Drivers

* AI INVESTMENTS - Blackbaud's ( BLKB ) significant investments in AI are empowering customers to improve efficiency and fundraising, as highlighted at the bbcon conference

* DIVESTITURE IMPACT - Revenue decline attributed to the divestiture of EVERFI, affecting GAAP results

* PRODUCTIVITY IMPROVEMENTS - Strong results reflect execution discipline and ongoing productivity improvements, per CFO Chad Anderson

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $281.10 $279.33

Revenue mln mln (5

Analysts

)

Q3 Beat $1.10 $1.07 (5

Adjusted Analysts

EPS )

Q3 $53.20

Adjusted mln

Net

Income

Q3 $99.70

Adjusted mln

EBITDA

Q3 $84 mln

Adjusted

Income

From

Operatio

ns

Q3 29.90%

Adjusted

Operatin

g Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy."

* Wall Street's median 12-month price target for Blackbaud Inc ( BLKB ) is $79.00, about 18.8% above its October 28 closing price of $64.15

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ambarella Insider Sold Shares Worth $406,006, According to a Recent SEC Filing
Ambarella Insider Sold Shares Worth $406,006, According to a Recent SEC Filing
Mar 20, 2026
04:27 AM EDT, 03/20/2026 (MT Newswires) -- John Alexander Young, Chief Financial Officer, on March 17, 2026, sold 7,615 shares in Ambarella ( AMBA ) for $406,006. Following the Form 4 filing with the SEC, Young has control over a total of 119,594 ordinary shares of the company, with 119,594 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1280263/000128026326000031/xslF345X05/edgardoc.xml ...
Astera Labs Insider Sold Shares Worth $20,723,773, According to a Recent SEC Filing
Astera Labs Insider Sold Shares Worth $20,723,773, According to a Recent SEC Filing
Mar 20, 2026
04:28 AM EDT, 03/20/2026 (MT Newswires) -- Jitendra Mohan, Director, Chief Executive Officer, on March 17, 2026, sold 157,500 shares in Astera Labs ( ALAB ) for $20,723,773. Following the Form 4 filing with the SEC, Mohan has control over a total of 8,984,472 common shares of the company, with 1,452,739 shares held directly and 7,531,733 controlled indirectly. SEC Filing:...
Revolution Medicines Insider Sold Shares Worth $427,965, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $427,965, According to a Recent SEC Filing
Mar 20, 2026
04:28 AM EDT, 03/20/2026 (MT Newswires) -- Stephen Michael Kelsey, President of Research and Development, on March 17, 2026, sold 4,302 shares in Revolution Medicines ( RVMD ) for $427,965. Following the Form 4 filing with the SEC, Kelsey has control over a total of 295,398 common shares of the company, with 295,398 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1628171/000161071726000131/xslF345X05/form4.xml ...
Alignment Healthcare Insider Sold Shares Worth $328,327, According to a Recent SEC Filing
Alignment Healthcare Insider Sold Shares Worth $328,327, According to a Recent SEC Filing
Mar 20, 2026
04:27 AM EDT, 03/20/2026 (MT Newswires) -- Hyong Kim, Chief Medical Officer, on March 18, 2026, sold 18,404 shares in Alignment Healthcare ( ALHC ) for $328,327. Following the Form 4 filing with the SEC, Kim has control over a total of 367,701 common shares of the company, with 367,701 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1832466/000162828026019918/xslF345X05/wk-form4_1773960141.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved